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Abstract. Background: Fanconi anemia (FA) is a rare 
genetic disease characterized by considerable heterogeneity 
Fifteen subtypes are currently recognised and deletions of 
the Fanconi anemia complementation group A I FANCA) gene 
account for more than 65% of FA cases. We report on the 
results from a cohort of 166 parients referred to the 
Department oj Medical Genetics of Al hens University for 
genetic investigation after the clinical suspicion of FA. 
Materials and Methods : For clastogen-mduced chromosome 
damage, cultures were set up with the addition of mitomycin 
C (MMC) and diepoxybutane (DEB), respectively. Following 
a positive cytogenetic result, molecular analysis was 
performed to allow identification of causative mutations in 
the FANCA gene. Results- A total of 13/166 patients were 
diagnosed with FA and 8/13 belonged to the FA-Α subtype. A 
novel point mutation was identified in exon 26 of FANCA 
gene. Conclusion: In our study 62% of FA patients were 
classified in the FA-Α subtype and a point mutation in exon 
26 was noted for the first time 
Fanconi anaemia (FA) is a rare genetic disorder, characterized 
by progressive pancytopenia, variable congenital anomalies, 
susceptibility to malignancies and induced chromosomal 
instability (1). Age of diagnosis ranges from birth io 50 years, 
with a mean onsei of anemia at eight years. Males and females 
arc equally affected. The incidence internationally is estimated 
lo be approximately 1/300000 and the carrier frequency 1/300. 
The highest rate is noticed in Aslikcnazi Jews ι earner 
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frequency 1/90. incidence 1/30000) and in Afrikaners in South 
Africa (heterozygote frequency 1/80, incidence 1/22000) (2). 
FA is characterized by progressive bone marrow failure. 
congenita] abnormalities and an increased risk for 
hematological malignancies and solid tumors. Physical 
abnormalities are presented in 60%-75% of affected 
individuals, including short stature, abnormal skin 
pigmentation, various malformations [skeletal system, eyes, 
kidneys and urinary tract, hearing loss, cardiovascular. 
gastrointestinal (Gl) and central nervous system). 
hypogonadism and developmental delay. Progressive bone 
marrow failure with pancytopenia typically presents in the first 
decade, often initially with thrombocytopenia or leukopenia ( I -
4) By age 40 to 50 years, the estimated cumulative incidence 
of bone marrow failure is 90%, incidence of haematological 
malignancy (primarily acute myeloid leukemia) 10%-30%, and 
of nonhematological malignancy (solid rumors, particularly of 
the head and neck, skin. Gl tract, and genital tract) 25%-30% 
(5-7). In addition to increased spontaneous chromosomal 
instability, cells from individuals with FA are sensitive to 
agents that cause tntcrstrand DNA cross-links, such as 
mitomycin C (MMC), bifunctional nitrogen mustards, 
diepoxybutane (DEB) and pholoactivated psoralens. 
On the genetic level there is considerable heterogeneity in 
FA and 15 subtypes/complementation groups are currently 
recognised. They all show autosomal recessive inheritance, 
with the exception of FA-B which i_ X-lmked. Genes and 
proteins of these subtypes have been identified {FANCA. 
FANCB. FANCC. FANCD1. FANCD2. FAN CE. FANCF. 
FANCG, FANC1. FANCJ, FANCL, FANCM, FANCN, FANCO, 
FANCP) (1,2,4.7-9). 
The FANC proteins cooperate in the Fanconi Anemia/ 
Breast Cancer (FA/ BRCA) pathway which may be divided 
in three parts: i) FA core complex, ii) complex of proteins 
FANCD2 and FANCI (ID complex) and in) downstream FA 
proteins (5. 10, 11. 12). The heterodimer ID complex. 
formed by FANCD2 and FANCI. is monoubiquitinated and 
then translocated to chromatin, interacting with downstream 
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proteins in the FA pathway in order to repair DNA defects 
by homologous recombination. In addition to DNA damage, 
the FA pathway can be activated during the S phase of the 
cell cycle (13-17). After DNA repair. FANCD2 and FANCI 
return to the non-ubiquinated form (11). 
The rale of identified mutations in the 15 FANC genes 
varies, but mutations of FANCA gene account for 
approximately 6 5 % of all cases diagnosed. The FANCA gene 
is mapped to chromosome I6q24.3, spans about 80 kb and 
consists of 43 exons Its mutation spectrum is very hetero-
genous and a number of point mutations, splicing mutations, 
large intragene deletions, probably Alu-mediated, or insertions 
have been described. Most detects are point mutations and 
about 30% are relatively large deletioas ( 2 , 4 , 9 , 17, 18). 
We report on the results from a cohort of 166 patients, aged 
2 months-40 years old referred to the Department of Medical 
Genetics of Athens University between 2007-2012 for genetic 
investigation after the clinical suspicion of FA (myelodysplasia 
and/or congenital anomalies). Skeletal, heart, pulmonary and 
kidney defects, developmental delay or squamous cell 
carcinoma were present in 13/166 patients, while 17/166 had 
(hematological and various congenital anomalies, and 133/166 
were referred because of anaemia, thrombocytopenia, 
pancytopenia, neutropenia .ind other hematological defects. 
Materials a n d Methods 
Cytogenetic analysis For clastogen-induced chromosome damage, 
cultures were set up with the addiuon of MMC and DEB, respectively 
The final concentration for MMC was 0.6 ug/ml and 1 ug/ml and cells 
were cultured for 72 hours In (he second set of culture·,, DEB was 
added 24 hours after initiation ai a final concentration of 0,1 ug/ml 
and cells were exposed to the chemical for 48 hours A minimum of 
ISO metaphases were examined and a sample was considered as FA-
posiuve if the percentage of breaks and radial formations detected 
were 7-10 times higher compared io an aged-matched control 
Molecular analysis. Following a positive cytogenetic result, molecular 
analysis was performed to allow identification ot causative mutations 
Genomic DNA was extracted from peripheral blood lymphocytes 
according to the protocol of an automated robotic system (QIAGEN 
BioROBOT M48, QiaGen. Hilden. Germany). Muluplex ligauon-
dependeni probe amplification (MLPA) was used for the detection of 
possible FANCA gene deletions Mutation analysis was performed by 
Polymerase chain réaction (PCR) amplification followed by En/ymatic 
cleavage mismatch analysis (ECMA). using the SURVEYOR™ 
Mutauon Detection Kit FANCA coding exons 1.7.25.26.28.32.33, 
34-35. 36,37,38,39,40-42. where a higher rate of molecular defects 
has been recorded, were amplified using primers designed by the 
Authors (Table I). PCR conditions were applied in order io provide 
the highest accuracy and specificity in the mutauon screening assay 
They included die activauon of polymerase (Hotstar taq/Multiplex) ai 
9S'C for 15 mu, followed by 33 cycles ol denaruration at 95 C for I 
mm. annealing ai 55 C lor I mm and cxtenuou d primers at 72 C lor 
Irmn and 72'C tor IO mia Dimethyl sulfoxide (UMSO) was used lor 
exon I because of C G-nth region, annealing oi this exon was at 58"C 
Samples demonstrating heteroduplex formation were directly 
Figure I Metaphase spread from a patient Kith Fanconi antamia. after 
exposure to mitomycin C iMMC). exhibiting multiple chromosomal 
breaks and radial formation' 
sequenced to allow characterization of molecular defects Sequencing 
reactions were performed with M13 universal primers using the 
DYEnamic ET Dye Terminator Cycle Sequencing kit and products 
were analyzed on a MegaBACE SNP Genolyping System (GE 
Healthcare I 
Results 
Cytogenetic testing. In 13/166 patients induced breaks and 
radial formations were noted with both clustogens in 96% of 
analysed metaphases (Figure 1). 
Molecular testing. Molecular analysis by MLPA revealed thai 
5/13 palients were classified as having the FA-Α subtype. 
Patients no. 1 and 2 were dizygotic twins and compound 
heterozygotes for the same deletions (exons 1-5 and 7-17) 
(Table II); patient no. 9 was a compound heterozygote for 
deletions of exons 1 and 2; patients no. 3 and 8 were carriers of 
deletions of exons 35 and 7-20, respectively (Table III). 
Among the eight remaining patients, three were identified as 
having FA-Α subtype due to point mutations in the FANCA 
gene Patient no. 6 earned the c-2T>C. p.Mel I ? in exon 1 and 
the c3788_3790delTCT;p.Phel263del in exon 38. Patients no. 
4 and 5 earned c.3348+18A>G in intron 33 (Figure 2) and 
c.2426 G>A; p.Gly809Asp in exon 26 (Figure 3). respectively. 
For patient no. 8, c3788_3790delTCT; p.Phel263del in exon 
38 was the compound detect (Table III). 
Out of 26 family members tested for carrier status, 13 
presented molecular alterations in the FANCA gene, five were 
heterozygotes for deletions of exons and eight were earners of 
point mutations. 
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Table I Primers (fonvard'reterse ) used in this study of Fanconi aneamia complémentation group A (FANCA) gene in Creek patients Each forward 
primer had a Ml3 tail (lowercase leners) to elaborate unner\al sequencing 
Etions Primers 
Forward Reverse 
I 
7 
25 li· 
28 
32 
33 
34 35 
36 
37 
38 
39 
40^2 
5'gtaaaacgacggccagtCCTGGCCGCAGCCAArAGG3' 
5'gtaaaacgacggceagl AGTTGAGCCTTACGTCTG3" 
5' gtaaaacgacgjecagtTGGATTAGCTGTTGGAGG3' 
S' giaaaacgacggccagrCTCAGCCACTCACAGTGA3· 
5" gtaaaacgacggccagrCTGCCAGCATACTGCTCn-
5' gtaaaacgacggccagtAAGGAGCAGAGTGTACGC3' 
5' glaaaacgacggixagtACAGCAGCCACTCTGCAT3· 
5'gtaaaacgacggccagtCCTGTAGTGGCCTGTAGG3" 
5 "gtaaaai.gacggLcagtTGGTTGTATGGTTGTAAG3 ' 
5'giaaaacgacggi.cagtTAGAATGACAGCACAGGT.y 
S •gxaaaacgacggccagrTAAG ACTT.AC AATAAGC A3 ' 
.S'gtaaaacgacggccagtAGC ACTG ATAATAGGC AG 3 ' 
5 ' CCGGCGG AGGCTCTGGCG 3 ' 
5AGAGCTCTTGAGAGCAGA3' 
5AACGAGCATGTGTCACTT3' 
S" GCTGTTCTTGCCTCTGAG3· 
5 TCTAGG ACCGTC ATG AG A3 ' 
5TGCAAGAGCTGCTGTTAG3' 
5ATGGAGACGTGCTGCAGA3· 
5 TTAGGAGATGACCTTGAG3 
5GAGAAATAGCACTGATTG3' 
5CTGGTAAGGTCTGACTTA3' 
5TGTGCCTCAGCAGCGTGT3' 
5GCTGTCAATTCTCATGTC 3' 
Clinical features of patients with FA are presented in Table 
III 
D i s c u s s i o n 
FA is a genetic condition that strongly predisposes patients to 
congeniiii] and haemaiologkal abnormalities. E*irly diagnosis 
is important, as long term survival depends on it. In future 
pregnancy, prenatal diagnosis can ensure an unaffected embryo, 
who may also represent an Human leukocyte antigen (HLA)-
compatible source of stem cells to be Iransplanted to an 
affected sibling. Cytogenetic analysis is the first essential step 
in the differential diagnosis from other types of anaemia, 
especially in cases when congenital abnormalities are absent 
and molecular testing reveals DNA defects, facilitating thus the 
genetic counselling of ihe family ( I, 2). FANCA. as the most 
frequently affected gene, displays the entire spectrum of 
genetic alterations, including al least 32% of large deletions 
correlated to Alu-mediated recombination The highest rate of 
FANCA molecular defects appears m the Spanish Gypsy 
population (=80%) (4, 6. 20, 21). 
In the present study, 13/166 patients were diagnosed with 
FA and. as expected. 62% of them (8/13) belonged to the FA-
A subtype, li is interesting to note that 38% of Ihe patients 
were Roma Gypsies. Both Spanish and Greek Gypsies are 
Roma, an ethnic group living mostly m Europe which has been 
genetically traced lo a group migrating from norlh-weslern 
India (22). It is also important to mention that of two patients, 
dizygotic twins, only the boy had VACTERL syndrome. In the 
literature there is a similar case report bur both twins diagnosed 
with FA had VACTERL syndrome (23). 
Molecular defects disclosed included large deletions (3/8) 
and point mutations (4/8) Exons 1, 7. 25-28, 32-42 of Ihe 
FANCA gene are reported in literature as those with the highest 
Table II Dizygotic twins, compound heterozygotes for Fanconi aneamia 
complementation group A (FANCA) gene deletions Deletion of exons 
1-5 is of paternal origin and thai of exons 7-17 it of maternal origin 
(Multiplex ligation-dependeni probe amplification -MLPA- technique) 
Each ratio corresponds io the fluorescent peak of each ampltcon which 
can be detected by a capillary sequencer. Ratios between the iwo 
alleles 0-O3-* patient 03-0 7-' carrier of deletion 0.7-1 J-» normal 
Exon of 
FANCA gene 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Id 
II 
12 
l i 
14 
15 
16 
17 
18 
19 
20 
Father 
0.52 
0.56 
0-53 
0.55 
0,55 
0.99 
0.98 
I.I 
1.12 
0.98 
0.97 
0.91 
I.I 
I 
0.97 
0.95 
1,11 
1.12 
1 
1 1 
Mother 
0 95 
094 
1.1 
1 
1 18 
1.08 
0.4 
036 
0.51 
0.5 
0.6 
0.48 
0.42 
0.49 
0.63 
0.54 
0-58 
0.91 
0.96 
0.99 
First twin 
052 
054 
055 
048 
0 57 
0.99 
0.42 
0.6 
052 
0.53 
052 
0.48 
054 
054 
0.48 
0.47 
0.48 
1 
0.98 
0.99 
Second twin 
052 
054 
055 
048 
057 
0 99 
042 
0 6 
052 
0.53 
052 
048 
054 
054 
0.48 
0.47 
0.48 
1 
0.98 
0.99 
mutational rate in the general population and could therefore 
be charactenzed as 'hot spots ' . c.3788_3790delTCT; 
p.Phel263del point mutation was detected in exon 38 and this 
is the most frequent FA mutation in Spain (20 . 7 % of all 
mutated alleles) and in the rest of the world (19, 2Λ). This 
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Figure 2. Point mutation c.3S48+l8A>G in mtron 33 of the Fanconi aneamia complementation group A (FANCA) gene. 
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Figure 3. The novel point mutauon c2->26 G>A: p.GIyS09Asp was identified tn exon 26 of the Fanconi aneamia complementation group A (FANCA) 
gene. 
Figure 4. Hypoplasia of the right thumb and aplasia of the left thumb. 
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Tabic 111. CΊ'inicalfeatures and molecular investigation of patients with Fanconi anaemia 
Panent 
1 
(dizygoüc twin 
of patient 2) 
2 
(dizygotic twin 
of patient 11 
a 
(Roma Gypsy) 
4 
Age 
6 Years 
6 Years 
6 Years 
95 Years 
Clinical features 
Microcephaly, hypennelanosis 
of die skin, petechias and 
pancytopenia 
VACTERL Syndrome, small stature. 
microcephaly, ocular ptosis. 
hypennelanosis of the skin. 
radial ray defect and pancytopenia 
Anaemia, thrombocytopenia 
Small stature, petechias, anaemia. 
microcephaly, redtal raj 
defect, hyperpigmentanon 
Mutations 
MLPA 
1-5 
and 
7-17 
1-5 
and 
7 17 
Carrier, deletion 
of exod 35 
PCR. ECMA/Sequencing 
-
-
Camere 3348+18 A>G 
in nitron 33 
Carriers in the family 
5 15 Years Aplasia of thumb, anaemia, horseshoe 
(Roma Gypsy) kidney, congenital cardiopathy 
(the parents are second cousins) 
Carrier of the poi nt 
mutation c.2426 G>A. 
p.Gly809Asp in exon 26. 
2/2 
2/2 
1/5 
1 4 
1/2 
10 
II 
12 
13 
5 Years Anaemia, thrombocytopenia, 
radial ray defect, short stature. 
hypopigmentauon 
6 Years Haematological deffects 
12 Years Haematological deflects 
9 25 Years 
(Roma Gypsy) 
Hypoplasia of the nght thumb 
and aplasia of the left 
thumb (Figure 4) 
7 Years Thrombocytopenia, anaemia. 
neutropenia, radial ray deffect 
3 Years Radial ray deffect 
17 Days Aplasia of the nght radius 
and thumb, hypogonadism. 
dysplastic kidney 
30 Years Anaemia, thrombocytopenia. 
MDS, aplasia of thumbs, 
-arc au lait spots 
Camer, deletion 
exons 7 20 
Camer ot t*o point 
mutations c.2T>C, p-Mctl? 
in the exon I and 
c.3788_3790delTCT; 
p.Phel263del in exon 38 
Carrier of the point mutation 
cJ788_3790delTCT. 
p.Phel263del in exon 38 
A ο 
Compound 
hetero7ygous for 
deletions of exons I and 2 
2/5 
mutation is shared hy 80% of patients from La Palma Island. highest frequency of FA reported). This mutation also accounts 
suggesting a founder effect that explains the extraordinary high for an elevated percentage (51%) of the mutations found in 
frequency of patients with FA in this island (1 in 16000. the Brazilian patients. 
1 
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The point mutation c. 3348+18A>G in intron 33 has been 
reported only once while c.2426 G>A, ρ Gly809Asp in exon 
26, to our knowledge, is reported for the first time in the 
present study. The mutation is already registered at the Leiden 
Open Variation Database (LOVD.i as a novel mutation and 
functional studies should be performed to allow 
characterization of its pathogenic impact (24). The carrier of 
this point mutation was a Roma Gypsy with typical features of 
FA born to consanguineous parents (second cousins) after an 
uneventful pregnancy (Table 111). 
In patient no. 3,4 and 5. a second molecular defect remains 
to be identified m order to elucidate the pathogenic mechanism 
underlying the presence of FA (Table Hit. The compound 
mutation may be located on the rest exons of FANCA gene 
where causative alterations are less frequent (19). Previous 
reports have disclosed that Roma Gypsies of Spanish origin 
share the 295C-»T mutation in exon 4. which m homozygotes. 
leads to FANCA truncation (20) This mutation was, however. 
not screened because the present study design of FA was based 
on the high mutational rate recorded for the general population 
and not specifically that for the Roma Gypsies (19). Further 
analysis is needed in order to identify the second defeci in the 
FANCA gene in the patients and ihcir relatives. 
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